查看文章

Many clinical reports have clearly shown the effectiveness of bromocriptine, a potent D2 receptors agonist, in reducing both plasma PRL levels and the size of most prolactinomas. These observations, along with the frequent failures of surgery, suggested the use of bromocriptine as first choice therapy of both microprolactinomas (mP) and macroprolactinomas (MP)(1-3). For this purpose the drug required to be administered two or three times a day, for long periods of treatment. The appearance of side effects: nausea, vomiting, orthostatic hypotension, particularly when high doses were necessary, could reduce patient's compliance and determine, in some instances, the withdrawal of the treatment. A long-acting form of bromocriptine, suitable for a once im injection (Parlodel LA, Sandoz), demonstrated to be very effective in reducing plasma PRL levels and tumor size, with an improved tolerability, in patients affected by MP over a period of 28 days (4-6). A new long-acting injectable form of bromocriptine, suitable for repeated administrations (Parlodel LAR, Sandoz), was the evolution of Parlodel LA. The aim of this study was to examine this new long-acting injectable